Dubai, 15th December, 2014: 42 market research a leading online-based market research agency, is pleased to announce that it has strengthened its capabilities and coverage in the Asia region, via its panels for Singapore, Malaysia, Indonesia and Philippines.
With growing demand for healthcare research studies in Asia, 42 market research has enhanced its panels for the new markets, thus being able to gain deeper insights from physicians and healthcare professionals across a wider spectrum and effectively penetrate the pharmaceutical market research industry in the region.
“The pharmaceutical market research sector in the South-East Asia region is growing rapidly and steadily in the recent times. By investing in these markets, 42 market research extends its coverage for its customers and continues to deliver the highest quality results” says Karen Olshanskiy, Market Research Manager. He continued “Having an ultimate goal to provide accurate, efficient and timely results, 42 market research is confident in its modernized techniques and its ability to adapt itself to the changing needs and requirements of its customers.”
About 42 market research
42 market research is an independent, internationally active, full-service market research provider for the healthcare industry. Healthcare-related professionals are interviewed in all major markets around the world concerning their experiences and opinions towards any health-related subject. The customers of 42 market research include pharmaceutical companies, other market research agencies, biotechnical companies, medical device manufacturers, health ministries and other businesses and organizations from within the healthcare sector. All panels are developed, operated, regularly updated, quality-controlled and owned exclusively by 42 market research. For further information, please visit www.42mr.com/jp.
42 market research
Public Relations Department
P.O. Box 211791
United Arab Emirates
Tel: +971 4 447 1540
Fax: +971 4 447 1542
For links to related websites, please click here.